Related Experiment Video
Updated: Jun 28, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Low-dose protracted irinotecan as a palliative chemotherapy for advanced neuroblastoma
Shinya Osone1, Hajime Hosoi, Kunihiko Tsuchiya
1Department of Pediatrics, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan.
Abstract:
Management of cases of refractory neuroblastoma remains a challenge. As intensive chemotherapy sometimes results in severe regimen-related toxicity and poor quality of life, palliative chemotherapy with modest toxicity may be considered for these cases. We report 2 cases of stage 4 neuroblastoma with poor performance status that received low-dose protracted schedules of irinotecan. This regimen achieved not only disease stabilization but also dramatic improvements of quality of life for significant periods. A low-dose protracted schedule of irinotecan was tolerable even if the patient's performance status was poor, and thus might be useful as a palliative chemotherapy for advanced neuroblastoma.
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Treatment Resistent Cancers
Treatment Resistant Cancers
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...